Interestingly, overexpression of FGF21 ameliorated hepatic steatosis and NASH symptoms of KD-fed Creb3l3−/− mice, suggesting that FGF21 is one of the major CREBH targets that help alleviate steatosis and NASH. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.